MedTrace Logo

A Multiple Dose Opioid Challenge Study

NCT02611752 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2019-11-14

Study results available
· View outcomes & findings →

Summary

Multi-site, randomized, double-blind, repeat-dose Phase 2 study to evaluate the degree and duration of action of multiple doses of CAM2038 in blocking the effects of hydromorphone in patients with moderate or severe opioid use disorder.

Conditions

  • Moderate or Severe Opioid Use Disorder

Interventions

DRUG

CAM2038

CAM2038 subcutaneous injection

Sponsors & Collaborators

  • Braeburn Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Sharon Walsh, PhD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02611752 on ClinicalTrials.gov